Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of GLPG1690 in systemic sclerosis
2018-001817-33Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing GLPG1690 with Placebo (2 arms). Primary endpoint: Change from baseline in mRSS over 24 weeks. Started Nov 2018; status: completed.
02
Drugs
ziritaxestat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2018-001817-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001817-33.